A Study of Lanabecestat in Participants With Severe Kidney Impairment Compared to Healthy Participants

Stopped Stopped for futility. Phase 3 studies not likely to meet primary endpoints.

Conditions

• Renal Insufficiency

Interventions

• DRUG: Lanabecestat
• DRUG: Iohexol

Sponsor

Eli Lilly and Company

Collaborators

• [object Object]